Business Context and Reporting Period
This Form 8-K Current Report was filed by Quince Therapeutics, Inc. on February 13, 2024. The report discloses a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the appointment of a director and associated compensation arrangements.
Material Changes
The material change reported is the appointment of Rajiv Patni as a director, effective February 15, 2024. Mr. Patni was designated as a Class III director with a term expiring at the 2025 Annual Meeting of Stockholders.
Management Commentary and Compensation Details
- Compensation: Mr. Patni is entitled to a $38,000 annual retainer under the Company's Outside Director Compensation Policy.
- Equity Grant: Upon appointment, Mr. Patni received a stock option award for 54,000 shares of common stock under the 2019 Equity Incentive Plan.
- Vesting Terms: The options vest in equal annual installments over a 3-year period, contingent on continued service.
- Exercise Price: Set at the closing sales price of the common stock on the grant date.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Patni.
Investor Verification Checklist
- Verify the effective date of the director appointment (February 15, 2024).
- Confirm the total number of shares covered by the new stock option grant (54,000 shares).
- Review the Company's 2019 Equity Incentive Plan for details on option exercise and vesting.
- Check the Company's most recent 10-Q or 10-K for updated financial position and cash runway, as this 8-K contains no financial metrics.